Progress in gene therapy for Duchenne muscular dystrophy

Gene transfer research for Duchenne muscular dystrophy (DMD) has brought the goal of successful treatment of this devastating, inherited disease closer to being a reality. Although gene therapeutic approaches for DMD patients are not yet in clinical use, recent advances using DMD animal models are e...

Full description

Saved in:
Bibliographic Details
Published in:Current neurology and neuroscience reports 2001, Vol.1 (1), p.89-96
Main Authors: Clemens, P R, Duncan, F J
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Cytoskeletal Proteins - therapeutic use
Gene therapy
Genetic Therapy
Genetic Vectors
Gentamicins - therapeutic use
Humans
Membrane Proteins - therapeutic use
Muscular dystrophy
Muscular Dystrophy, Duchenne - drug therapy
Muscular Dystrophy, Duchenne - genetics
Muscular Dystrophy, Duchenne - therapy
Utrophin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83
cites cdi_FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83
container_end_page 96
container_issue 1
container_start_page 89
container_title Current neurology and neuroscience reports
container_volume 1
creator Clemens, P R
Duncan, F J
description Gene transfer research for Duchenne muscular dystrophy (DMD) has brought the goal of successful treatment of this devastating, inherited disease closer to being a reality. Although gene therapeutic approaches for DMD patients are not yet in clinical use, recent advances using DMD animal models are encouraging. Progress in vector design, such as high-capacity adenoviral vectors, targeted adenoviral vectors, and heterodimerization of DNA delivered by adeno-associated virus (AAV) vectors have advanced the field considerably. The recent studies into the pharmacologic-induced read-through of stop codons, the increased study of utrophin and its upregulation, and the introduction of point mutation correction using chimeric oligonucleotides have expanded the field, providing new avenues of inquiry.
doi_str_mv 10.1007/s11910-001-0080-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71289415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2409855481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83</originalsourceid><addsrcrecordid>eNpdkE1LxDAQhoMo7rr6A7xI8eCtOpOkbXKU9RMW9KDn0KbT_WD7YdIe-u9N2QXBwzDD8L7DvA9j1wj3CJA9eESNEANgKBWGEzbHRMg45VqcTjNXsQTJZ-zC-x0ADy59zmaISqsE5JypT9euHXkfbZtoTQ1F_YZc3o1R1broabAbasKyHrwd9rmLytH3ru024yU7q_K9p6tjX7Dvl-ev5Vu8-nh9Xz6uYsuF7mORc5tZK6jgZZ7YVIJQJcgKBRFQaguAwkLIQSrJSompRk4JgUZp88IqsWB3h7uda38G8r2pt97Sfp831A7eZMiVliH1gt3-E-7awTXhN6MynaYcUwgiPIisa713VJnObevcjQbBTEzNgakJTM3E1Eyem-Phoaip_HMcIYpfuIlwxw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879662160</pqid></control><display><type>article</type><title>Progress in gene therapy for Duchenne muscular dystrophy</title><source>Springer Nature</source><creator>Clemens, P R ; Duncan, F J</creator><creatorcontrib>Clemens, P R ; Duncan, F J</creatorcontrib><description>Gene transfer research for Duchenne muscular dystrophy (DMD) has brought the goal of successful treatment of this devastating, inherited disease closer to being a reality. Although gene therapeutic approaches for DMD patients are not yet in clinical use, recent advances using DMD animal models are encouraging. Progress in vector design, such as high-capacity adenoviral vectors, targeted adenoviral vectors, and heterodimerization of DNA delivered by adeno-associated virus (AAV) vectors have advanced the field considerably. The recent studies into the pharmacologic-induced read-through of stop codons, the increased study of utrophin and its upregulation, and the introduction of point mutation correction using chimeric oligonucleotides have expanded the field, providing new avenues of inquiry.</description><identifier>ISSN: 1528-4042</identifier><identifier>EISSN: 1534-6293</identifier><identifier>DOI: 10.1007/s11910-001-0080-0</identifier><identifier>PMID: 11898504</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Cytoskeletal Proteins - therapeutic use ; Gene therapy ; Genetic Therapy ; Genetic Vectors ; Gentamicins - therapeutic use ; Humans ; Membrane Proteins - therapeutic use ; Muscular dystrophy ; Muscular Dystrophy, Duchenne - drug therapy ; Muscular Dystrophy, Duchenne - genetics ; Muscular Dystrophy, Duchenne - therapy ; Utrophin</subject><ispartof>Current neurology and neuroscience reports, 2001, Vol.1 (1), p.89-96</ispartof><rights>Current Science Inc. 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83</citedby><cites>FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11898504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Clemens, P R</creatorcontrib><creatorcontrib>Duncan, F J</creatorcontrib><title>Progress in gene therapy for Duchenne muscular dystrophy</title><title>Current neurology and neuroscience reports</title><addtitle>Curr Neurol Neurosci Rep</addtitle><description>Gene transfer research for Duchenne muscular dystrophy (DMD) has brought the goal of successful treatment of this devastating, inherited disease closer to being a reality. Although gene therapeutic approaches for DMD patients are not yet in clinical use, recent advances using DMD animal models are encouraging. Progress in vector design, such as high-capacity adenoviral vectors, targeted adenoviral vectors, and heterodimerization of DNA delivered by adeno-associated virus (AAV) vectors have advanced the field considerably. The recent studies into the pharmacologic-induced read-through of stop codons, the increased study of utrophin and its upregulation, and the introduction of point mutation correction using chimeric oligonucleotides have expanded the field, providing new avenues of inquiry.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Cytoskeletal Proteins - therapeutic use</subject><subject>Gene therapy</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors</subject><subject>Gentamicins - therapeutic use</subject><subject>Humans</subject><subject>Membrane Proteins - therapeutic use</subject><subject>Muscular dystrophy</subject><subject>Muscular Dystrophy, Duchenne - drug therapy</subject><subject>Muscular Dystrophy, Duchenne - genetics</subject><subject>Muscular Dystrophy, Duchenne - therapy</subject><subject>Utrophin</subject><issn>1528-4042</issn><issn>1534-6293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpdkE1LxDAQhoMo7rr6A7xI8eCtOpOkbXKU9RMW9KDn0KbT_WD7YdIe-u9N2QXBwzDD8L7DvA9j1wj3CJA9eESNEANgKBWGEzbHRMg45VqcTjNXsQTJZ-zC-x0ADy59zmaISqsE5JypT9euHXkfbZtoTQ1F_YZc3o1R1broabAbasKyHrwd9rmLytH3ru024yU7q_K9p6tjX7Dvl-ev5Vu8-nh9Xz6uYsuF7mORc5tZK6jgZZ7YVIJQJcgKBRFQaguAwkLIQSrJSompRk4JgUZp88IqsWB3h7uda38G8r2pt97Sfp831A7eZMiVliH1gt3-E-7awTXhN6MynaYcUwgiPIisa713VJnObevcjQbBTEzNgakJTM3E1Eyem-Phoaip_HMcIYpfuIlwxw</recordid><startdate>2001</startdate><enddate>2001</enddate><creator>Clemens, P R</creator><creator>Duncan, F J</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>2001</creationdate><title>Progress in gene therapy for Duchenne muscular dystrophy</title><author>Clemens, P R ; Duncan, F J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Cytoskeletal Proteins - therapeutic use</topic><topic>Gene therapy</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors</topic><topic>Gentamicins - therapeutic use</topic><topic>Humans</topic><topic>Membrane Proteins - therapeutic use</topic><topic>Muscular dystrophy</topic><topic>Muscular Dystrophy, Duchenne - drug therapy</topic><topic>Muscular Dystrophy, Duchenne - genetics</topic><topic>Muscular Dystrophy, Duchenne - therapy</topic><topic>Utrophin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Clemens, P R</creatorcontrib><creatorcontrib>Duncan, F J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Current neurology and neuroscience reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Clemens, P R</au><au>Duncan, F J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progress in gene therapy for Duchenne muscular dystrophy</atitle><jtitle>Current neurology and neuroscience reports</jtitle><addtitle>Curr Neurol Neurosci Rep</addtitle><date>2001</date><risdate>2001</risdate><volume>1</volume><issue>1</issue><spage>89</spage><epage>96</epage><pages>89-96</pages><issn>1528-4042</issn><eissn>1534-6293</eissn><abstract>Gene transfer research for Duchenne muscular dystrophy (DMD) has brought the goal of successful treatment of this devastating, inherited disease closer to being a reality. Although gene therapeutic approaches for DMD patients are not yet in clinical use, recent advances using DMD animal models are encouraging. Progress in vector design, such as high-capacity adenoviral vectors, targeted adenoviral vectors, and heterodimerization of DNA delivered by adeno-associated virus (AAV) vectors have advanced the field considerably. The recent studies into the pharmacologic-induced read-through of stop codons, the increased study of utrophin and its upregulation, and the introduction of point mutation correction using chimeric oligonucleotides have expanded the field, providing new avenues of inquiry.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11898504</pmid><doi>10.1007/s11910-001-0080-0</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1528-4042
ispartof Current neurology and neuroscience reports, 2001, Vol.1 (1), p.89-96
issn 1528-4042
1534-6293
language eng
recordid cdi_proquest_miscellaneous_71289415
source Springer Nature
subjects Anti-Bacterial Agents - therapeutic use
Cytoskeletal Proteins - therapeutic use
Gene therapy
Genetic Therapy
Genetic Vectors
Gentamicins - therapeutic use
Humans
Membrane Proteins - therapeutic use
Muscular dystrophy
Muscular Dystrophy, Duchenne - drug therapy
Muscular Dystrophy, Duchenne - genetics
Muscular Dystrophy, Duchenne - therapy
Utrophin
title Progress in gene therapy for Duchenne muscular dystrophy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A03%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progress%20in%20gene%20therapy%20for%20Duchenne%20muscular%20dystrophy&rft.jtitle=Current%20neurology%20and%20neuroscience%20reports&rft.au=Clemens,%20P%20R&rft.date=2001&rft.volume=1&rft.issue=1&rft.spage=89&rft.epage=96&rft.pages=89-96&rft.issn=1528-4042&rft.eissn=1534-6293&rft_id=info:doi/10.1007/s11910-001-0080-0&rft_dat=%3Cproquest_cross%3E2409855481%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c239t-3a2c7cc3eb2da5c64038d04f13ee0e6cb00bc0119e857d416912e5e0914cabc83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=879662160&rft_id=info:pmid/11898504&rfr_iscdi=true